Explore by Category
ASH 2021: Meet Valarie Traynham - Personalized Medicine for a Personal Disease
MYELOMA NEWS - December 04, 2021
Fostering community and change are essential parts of Valarie Traynham’s DNA. After her diagnosis she started attending a local support group and so... Read More
ASH 2021: Myeloma Crowd by HealthTree Has ASH Covered
MYELOMA NEWS - December 03, 2021
The annual American Society of Hematology (ASH) meeting is the most important important meeting of the year for medical professionals working in myeloma. ... Read More
Darzalex FASPRO Gets FDA Approval for Use With Carfilzomib and Dexamethasone
MYELOMA NEWS - December 01, 2021
Darzalex FASPRO (the subcutaneous shot of daratumumab) has received its ninth FDA approval, this time with use in combination with carfilzomib and dexamethasone... Read More
A Potential Warning Sign for Allo CAR T in Multiple Myeloma
MYELOMA NEWS - November 24, 2021
Myeloma Crowd by HealthTree has posted several articles recently here and here about the potential of donor CAR-T cell therapy. These CAR-T cells have the ... Read More
Dual Myeloma CAR T Targeting BCMA and CD19 Gets FDA Orphan Drug Designation
MYELOMA NEWS - November 23, 2021
China-based Gracell Biotechnologies was recently given FDA Orphan Drug designation for a dual CAR T targeting BCMA and CD19 in multiple myelom... Read More
New Genetic Subdivisions Help Separate Myeloma Risk and Potentially Personalize Treatments
MYELOMA NEWS - November 19, 2021
Mount Sinai researchers have identified new ways of classifying myeloma sub-types to define risk in a paper published in Science Advances. The new tool, c... Read More
FDA Extends Janssen's Cilta-Cel PDUFA Date
MYELOMA NEWS - November 02, 2021
Janssen announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) date for the CAR T therapy, cilta-cel) Biologics License Application. The... Read More
The Man Who Changed Cancer Forever: Meet Jim Allison, November 15th @ 3 PM Eastern
MYELOMA NEWS - October 29, 2021
“Wondrous." That’s how Nobel Prize-winning immunotherapy pioneer Jim Allison sums up the promise of immunotherapy to help the human immun... Read More
Why Oncopeptides Withdrew its FDA Application for Melflufen (PEPAXTO) in Multiple Myeloma
MYELOMA NEWS - October 27, 2021
Oncopeptides AB has decided to withdraw their US FDA application for melflufen, but will continue to support myeloma patients currently on the drug. ... Read More
A New Type of CAR Multiple Myeloma Therapy: CAR NK Cells
MYELOMA NEWS - October 21, 2021
Researchers in Spain believe that a new type of CAR therapy using natural killer cells, could be more effective and have fewer side effects in treat... Read More
Join Nobel Prize Winner and Immunotherapy Pioneer Dr. Jim Allison on November 15th @ 3 PM Eastern
MYELOMA NEWS - October 15, 2021
On November 15th, 2021 at 3 PM Eastern we will have the unique opportunity to hear from Nobel Prize Winner and Immunotherapy Pioneer, Dr. Jim Allison, and his w... Read More
Myeloma Patient Responses to the COVID Vaccine with Dr. Parekh and Dr. Van Oekelen, Oct 27 @ 3pm Eastern
MYELOMA NEWS - October 12, 2021
The Myeloma Crowd Community program is pleased to welcome Drs. Samir Parekh and Oliver Van Oekelen ashare findings from their studies about how myelom... Read More
IMW: Iberdomide Demonstrates Ability to Overcome Resistance to Common Myeloma Therapies
MYELOMA NEWS - October 07, 2021
A new drug called iberdomide when combined with daratumumab, bortezomib or carfilzomib is showing positive effects with fewer side effects than its predecessor ... Read More
. 
. 
